Showing results (151-160 of 214) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancerJohanna C Bendell, John Nemunaitis, Sasha J Vukelja, et al.
Technology and Health Care : Official Journal of the European Society for Engineering and Medicine|August 2, 2017
A novel PLIF PEEK interbody cage with an impactionless insertion technology: A case series with a mid-term follow up of three yearsCharlotte Struwe, Pia C Hermann, Rahel Bornemann, et al.
Global Public Health|July 3, 2026
Perceptions, knowledge, and access to the HPV vaccine among parents and healthcare providers in South Quito, Ecuador in 2025: A qualitative studyKallin C Hermann, Alejandro Andrés Peralta Chiriboga, Kevin T Fuji, et al.
Cancers|September 28, 2021
Deletion of NEMO Inhibits EMT and Reduces Metastasis in KPC MiceMiltiadis Tsesmelis, Kanishka Tiwary, Katja Steiger, et al.
Skin Pharmacology : the Official Journal of the Skin Pharmacology Society|January 1, 1988
Topical ciclosporin for psoriasis: in vitro skin penetration and clinical studyR C Hermann, R S Taylor, C N Ellis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2000
Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatinF A Greco, J B Erland, L H Morrissey, et al.
Kidney International|February 15, 2007
Inhibition of the mammalian target of rapamycin impedes lymphangiogenesisS Huber, C J Bruns, G Schmid, et al.
Lancet (London, England)|November 24, 1990
Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patientsN F Olivieri, G Koren, C Hermann, et al.
Genes and Immunity|May 6, 2005
Chronic periodontal disease is associated with single-nucleotide polymorphisms of the human TLR-4 geneN W J Schröder, D Meister, V Wolff, et al.
Molecular Cancer Therapeutics|February 2, 2013
Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell linesAngélique Augustin, Jens Lamerz, Hélène Meistermann, et al.
Pageof 22